FASN and Alzheimer disease: Given the increasing body of evidence linking HSV-1 to the onset of AD and the demonstrated neuroprotective effects of CMS121 — a fisetin-derived FASN inhibitor (FASNi) that reduces cognitive decline in mice [20,21] — we aimed to evaluate its impact on HSV-1 replication.